We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Rectangle Image
News

Gen9, Arzeda Announce Supply Agreement for Synthetic DNA

Rectangle Image
News

Gen9, Arzeda Announce Supply Agreement for Synthetic DNA

Read time:
 

Gen9 and Arzeda today announced an agreement for the supply of megabase quantities of synthetic DNA that will enable Arzeda to accelerate development of novel molecules for its own products as well as those of its partners. The collaboration is part of Gen9’s Multiplex Access Partnership (MAP) program, designed to provide industrial users of synthetic DNA with access to game-changing economics for synthetic DNA.

“Through Gen9’s MAP we have access to millions of base pairs of DNA, enabling us to ramp up the development of novel and valuable molecules to help make the food we eat, the products we buy and the air we breathe less toxic and more sustainable,” said Alexandre Zanghellini, Arzeda’s co-founder and CEO. “We are revolutionizing the way chemicals are produced and Gen9’s capabilities are a perfect fit for our technology.” 

The Gen9 MAP program is fueled by Gen9’s BioFab® DNA synthesis platform, enabling the manufacture of mass quantities of high quality, long-length clonal DNA. Arzeda will utilize Gen9 synthetic DNA as part of its program to create a portfolio of enzymes and specialty chemicals for polymers, novel crop traits, pharmaceuticals, industrial chemicals and other advanced materials. Arzeda’s proprietary technology combines computational enzyme and pathway design with state-of-the-art bioengineering to create entirely novel designer cell factories capable of industry-scale chemical production. 

“We see synthetic biology as a foundational approach for enormous value creation, whether it be reducing the environmental footprint of a chemical manufacturing process or engineering a pathway to more efficiently and cost-effectively produce high value molecules,” said Kevin Munnelly, President and CEO of Gen9. “We are thrilled to work with Arzeda and look forward to the critical advancements our combined efforts will drive.”

Advertisement